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A B S T R A C T
Nutritional support, addressing the specific needs of this patient group, is required to help improve prognosis, and re-
duce the consequences of cancer-associated nutritional decline. Early intervention with nutritional supplementation has
been shown to halt malnutrition, and may improve outcome in some patients. In our study we tried to assess the influence
of nutritional support (counseling, oral liquids, megestrol acetate) on nutritional status and symptoms prevalence in pa-
tients with colorectal cancer during chemotherapy. Group I consisted of 215 (55%) patients with medium age 68  2.6
years who were monitored prospectively and were given nutritional support. Group II included 173 (45%) patients (me-
dium age 67  2.9 years) without the proper nutritional counseling, in whom the data were collected retrospectively dur-
ing a 6 years period of time. After evaluation Nottingham Screening Tool Score, Appetite Loss Scale and Karnofsky Per-
formance Status) all patients in the group I received nutritional counseling, 153 of them (72%) were taking form of
enteral food supplement and 103 (48%) patients were using megestrol acetate. Evaluating the initial risk measurements
according to BMI, decrease in weight gain and NST, we did not find any significant difference between the two groups.
After chemotherapy completion, patients in group I had a 15.3% drop of those who’s BMI was <20,65% patients in-
creased their body weight, with an average weight gain of 1.5 kg (0.6–2.8 kg). Contrary, in group II we found increase in
weight loss ³2 kg/month in 39% of patients. The appetite improvement was detected on Appetite Loss Scale from 3.1
(pre-chemotherapy) to 4.7 (post-chemotherapy) in group I, especially in those receiving megestrol acetate. In both groups
Karnofsky Performance Status didn’t change significantly reflecting the impact of the disease itself and chemotherapy
procedures to the patient’s condition. Nutritional counseling, supplemental feeding and pharmacological support do
temporarily stop weight loss and improve appetite, social life and quality of life in those groups of patients. However, this
improvement have no implications on patients KPS and course of their disease.
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Introduction
Colorectal cancer is the significant cause of morbidity
and mortality in the developed countries with approxi-
mately equal number of new cases annually in men and
women1. Despite deep knowledge concerning morpho-
genesis and spread of colorectal carcinoma as well as vast
achievements in surgery, chemo- and radiotherapy, the
percentage of 5-year-survivals is still poor and reaches 15%.
According to the most authors, there are four risk factor
categories: epidemiological, intestinal, dietetic, and mixed.
It is well known that colorectal cancer is a disease, in
which genetic mutations of somatic cells are the molecu-
lar base of the disease. The inner innervation of the colon
seems to play an important role in carcinoma pathoge-
nesis and spread2,3. Today, about 50% of colorectal carci-
nomas are diagnosed in the advanced stage, with infiltra-
tion exceeding the intestinal wall or spreadng to neighboring
organs, which gives full clinical symptoms. The prognosis
for the survival after disease progression is usually poor4.
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Tumor growth is associated with profound metabolic
and neurochemical alterations, which can lead to the on-
set of anorexia-cachexia syndrome. Anorexia is defined
as the loss of the desire to eat, while cachexia results
from progressive wasting of skeletal muscle mass, and to
a lesser extent adipose tissue, occurring even before
weight loss becomes apparent. Cancer anorexia-cachexia
syndrome is highly prevalent among cancer patients, has
a large impact on morbidity and mortality, and on patient
quality of life5. According to clinical studies, increasing
caloric intake does not reverse cachexia. The patho-
physiology of cachexia involves more complex mecha-
nisms than simply caloric deficiency. The process appears
to be mediated by circulating catabolic factors, either se-
creted by the tumor alone or in association with host-de-
rived factors, such as Tumor necrosis factor-a (TNF-a),
interleukins (IL-1, IL-6), interferon-g (IFN-g) and Leuke-
mia inhibitory factor (LIF)6.
The consequences of malnutrition include impair-
ment of immune functions, performance status, muscle
function, and quality of life. In addition, responses to
chemotherapy are decreased, chemotherapy-induced tox-
icity and complications are more frequent and severe,
and survival times are shortened7.
Nutritional support, addressing the specific needs of
this patient group, is required to help improve prognosis,
and reduce the consequences of cancer-associated nutri-
tional decline8. Because weight loss shortens the survival
time of cancer patients and decreases performance sta-
tus, effective therapy would extend patient survival and
improve quality of life9.
Early intervention with nutritional supplementation
has been shown to halt malnutrition, and may improve
outcome in some patients. However, increasing nutri-
tional intake is insufficient to prevent the development
of cachexia, reflecting the complex pathogenesis of this
condition10.
In our study we tried to assess the influence of nutri-
tional support (counseling, oral liquids, megestrol ace-
tate) on nutritional status and symptoms prevalence in
patients with colorectal cancer during chemotherapy.
Patients and Methods
Three hundred and eighty-eight patients were in-
cluded in the study in the period of time from January
2001. to December 2007. The study took place at Gastro-
enterology department, Clinical Hospital Centre Rijeka.
According to the given nutritional support, patients were
divided in the two groups. Group I consisted of 215 (55%)
patients who were monitored prospectively and were
given nutritional support. Group II included 173 (45%)
patients without the proper nutritional counseling, in
whom the data were collected retrospectively during a 6
years period of time. Seventy-four (43%) patients in
group II and 80 (37%) in group I had locally advanced
and/or metastatic disease before chemotherapy initiation.
Four weeks after operation (if needed) and one week
before chemotherapy initiation, we undertook initial eval-
uation of the patient’s nutritional status (visit 0). Nutri-
tional status was evaluated according to body weight
change. BMI was calculated for all patients by using the
standard procedure dividing weight in kg by height in
m2. Patients were also evaluated through three question-
naires: Nottingham Screening Tool Score (NST score,
0–7) (Table 1), Appetite Loss scale (0–10) and Karnofsky
Performance Status (KPS, 0–100%). Patients who were
considered to have nutritional risk, were those with
BMI<20, decrease in weight gain>2 kg/month and NST
score ³5.
Nutritional and pharmacological support was given to
all patients in group I. Support included nutritional
counseling, prescription of megestrol acetate 400 mg
daily and supplementary/adjuvant enteral nutrition. Nu-
tritional counseling included interview with physician,
instructions for food preparation during chemotherapy,
encouraging patients to eat more meals a day and to
change bad eating habits.
All patients in the group I received nutritional coun-
seling, 153 of them (72%) were taking form of enteral
food supplement and 103 (48%) patients were using
megestrol acetate.
All patients with locally advanced (TNM – T3 or T4)
and/or metastatic disease (TNM – M1) were treated with
the standard first line-treatment, receiving a standard
regime combinations of FOLFIRI/XELIRI or FOLFOX
protocol.
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TABLE 1
NOTHINGAM SCREENING TOOL QUESTIONNAIRE
Nothingam Screening Tool Questionnaire
0 – BMI > 20
1 – BMI 18–20
2 – BMI <18
Has the patient unintentionally lost weight during last 3 months?
0 – no
1 – a little, up to 3 kg
2 – a lot, more than 3 kg




Stress factor/severity of illness?
0 – none
1 – moderate (uncomplicated operation, chronic disease,
infection, etc.
2 – severe (multiple fractures and wounds, sepsis, can-
cers, major operation, etc)
Score 0–2 Patient do not need nutritive support
Score 3–4 Patient had to be monitored once more in week
Score ³ 5 Patient has malnutrition and need nutritive counsel-
ing and support
During the follow-up, we performed 12 visits accord-
ing to chemotherapy schedule. On each consecutive visit,
before chemotherapy initiation, patient’s nutritional status
was re-evaluated using above mentioned evaluation tools.
Results
Evaluating the initial risk measurements according to
BMI, decrease in weight gain and NST, we did not find
any significant difference between the two groups (42%
vs. 48%, 42% vs. 45% and 45% vs. 52%, respectively).
After chemotherapy completion, patients in group I
had a 15.3% drop of those who’s BMI was < 20. An oppo-
site 12.1% raise in patients with BMI < 20 was noted in
the group without nutritional support.
Similar direction was observed between the two groups
when we monitored weight loss > 2 kg/month. In group I
65% patients increased their body weight, with an aver-
age weight gain of 1.5kg (0.6–2.8kg). Weight gain was
mostly expressed in group I in patients receiving me-
gestrol acetate after 4 weeks-therapy. Contrary, in group
II we found increase in weight loss ³2 kg/month in 39% of
patients. The appetite improvement was detected on Ap-
petite Loss Scale from 3.1 (pre-chemotherapy) to 4.7
(post-chemotherapy) in group I, especially in those re-
ceiving megestrol acetate (Table 2, Table 3).
In group I no significant difference in KPS score was
observed, from 74.2% before chemotherapy to 80.4% af-
ter the chemotherapy completion. Also in group II, KPS
score was 70.4% before chemotherapy and didn’t change
significantly – 70.2% after chemotherapy.
Most obvious side effects of enteral food supplemen-
tation was diarrhea in 12% (19) of patients, followed by
abdominal pain in 9% (14) and bad taste occurring in 5%
of patients (8). Water retention with resultant edema
was the main side effect experienced in 20% of patients
receiving megestrol acetate.
Discussion
The role of nutrition therapy is often assumed to be
less important than pharmacologic interventions as out-
comes are less clear in literature. There is general failure
to recognize weight loss early enough and to implement
effective nutrition interventions11,12,13.
Our study showed that early nutritional intervention
and adequate counseling can decrease or even reverse
course of weight deterioration in the early course of lo-
cally advanced or metastatic CRC.
Sixty-five percent of patients increased weight and
additional 9% maintained weight during chemotherapy.
All patients receiving megestrol acetate were weight
gainers.
Studies that analyzed progestational agents, such as
megestrol acetate and medroxyprogesterone, showed ap-
petite improvement and weight increase in advanced
cancer patients with slight increase in risk of throm-
bophlebitis14,15.
Megestrol acetate induced edemas in some patients,
but didn’t cause any other serious side effect. It seemed
that improved social life due to the better appetite was
more important for patients than discomfort caused by
edema. Even though we have found a difference in KPS
between the two groups, our result was not statistically
significant, leading us to conclusion that nutritional sup-
port had no implications on patients KPS and disease
course.
Karnofsky Performance Status didn’t change signifi-
cantly reflecting the impact of the disease itself and che-
motherapy procedures to the patient’s condition.
We have concluded that nutritional counseling, sup-
plemental feeding and pharmacological support do tem-
porarily stop weight loss and improve appetite, social life
and quality of life in those groups of patients. However,
this improvement have no implications on patients KPS
and course of their disease. Due to a small number of pa-
tients and short follow up, we are unable to evaluate the
impact of improved nutritional status on a patient’s sur-
vival.
To achieve compliance, nutrition therapy should be
implemented in an aggressive manner. The clinician is
therefore faced with the need to recognize nutrition-re-
lated issues and to implement effective strategies that
will lead to positive outcome for patients.
R. Dobrila Dintinjana et al.: Nutritional Support in Patients with Colorectal Cancer, Coll. Antropol. 32 (2008) 3: 737–740
739
TABLE 3
NUMBER OF PATIENTS IN GROUP II (N=173) WITH BMI<20,






BMI <20 71 (41.04%) 92 (53.18%)
NTS ³5 78 (45.09%) 101 (58.38%)
Loss of appetite 115 (66.47%) 156 (90.17%)
Decreasing in weight
gain (>2kg/month)
72 (41.62%) 140 (80.92%)
TABLE 2
NUMBER OF PATIENTS IN GROUP I (N=215) WITH BMI<20,






BMI <20 105 (48.84%) 72 (33.49%)
NTS ³5 112 (52.10%) 75 (34,88%)
Loss of appetite 168 (78.14%) 81 (37,67%)
Decreasing in weight
gain (>2kg/month)
97 (45.12%) 56 (26.05%)
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U^INCI NUTRITIVNE POTPORE U BOLESNIKA S RAKOM DEBELOG CRIJEVA
ZA VRIJEME KEMOTERAPIJE
S A @ E T A K
Nutritivna potpora, usmjerena prema specifi~nim potrebama ove grupe bolesnika pobolj{ava prognozu i umanjuje
posljedice nutritivnog propadanja povezanog s karcinomom. Rana nutritivna potpora smanjuje mogu}nost nastanka
malnutricije i mo`e pobolj{ati ishod bolesti u nekih bolesnika. U na{oj studiji nastojali smo ocijeniti u~inak nutritivne
potpore (savjetovanje, teku}i peroralni pripravci, megestrol acetat) na nutritivni status i u~estalost simptoma u na{ih
bolesnika s rakom debelog crijeva za vrijeme kemoterapije. Prva grupa bolesnika se sastojala od 215 (55%) bolesnika
srednje `ivotne dobi 68  2,6 godina koji su promatrani u prospektivnoj studiji i koji su primili nutritivnu potporu.
Druga grupa se sastojala od 173 (45%) bolesnika (srednje `ivotne dobi 67  2,9 godina) bez pravilnog nutritivnog savje-
tovanja, za koje su se podaci prikupili za razdoblje od 6 godina retrospektivno. Nakon evaluacije Nottingham Screening
Tool bodovanjem, skale za gubitak apetita i Karnofsky Performance stanja, svi bolesnici iz prve grupe su »nutritivno«
savjetovani; 153 (72%) bolesnika je dobilo teku}e enteralne nadomjesne pripravke a 103 (48%) bolesnika je po~elo uzi-
mati megestrol acetat. Izme|u navedene dvije grupe nije bilo statisti~ki zna~ajnih razlika u indeksu tjelesne mase,
smanjenju tjelesne te`ine i Nottingham Screening Tool bodovanju. Po zavr{etku ciklusa kemoterapije, u 65% bolesnika
iz prve grupe zabilje`en je porast tjelesne te`ine od 1,5 kg (0,6–2,8 kg). Nasuprot tome, u drugoj grupi zabilje`ili smo
smanjenje u tjelesnoj te`ini >2 kg na mjesec u 39% bolesnika. U prvoj grupi zabilje`eno je pobolj{anje apetita (na skali
za apetit) od 3,1 (prije kemoterapije) na 4,7 (poslije kemoterapije) i to naro~ito u grupi bolesnika koji su primali mege-
strol acetat. Karnofsky Performance Status se nije zna~ajno mijenjao u obje grupe, odra`avaju}i tako utjecaj bolesti
»same za sebe« i postupka kemoterapije na stanje bolesnika. Nutritivno savjetovanje, nadomjesna ishrana i farmako-
lo{ka potpora privremeno zaustavljaju gubitak tjelesne te`ine i popravljaju apetit, socijalnu komponentu `ivota i kva-
litetu `ivota u tim grupama bolesnika. Ipak, to pobolj{anje nema implikacija na sam status bolesnika i tijek njihove
bolesti.
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